Source: EURLEX
Language: es
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 25.7.2015 | ES | Diario Oficial de la Unión Europea | L 197/10 |

---

REGLAMENTO (UE) 2015/1221 DE LA COMISIÓN

de 24 de julio de 2015

por el que se modifica el Reglamento (CE) no 1272/2008 del Parlamento Europeo y del Consejo sobre clasificación, etiquetado y envasado de sustancias y mezclas, a efectos de su adaptación al progreso técnico y científico

(Texto pertinente a efectos del EEE)

LA COMISIÓN EUROPEA,

Visto el Tratado de Funcionamiento de la Unión Europea,

Visto el Reglamento (CE) no 1272/2008 del Parlamento Europeo y del Consejo, de 16 de diciembre de 2008, sobre clasificación, etiquetado y envasado de sustancias y mezclas, y por el que se modifican y derogan las Directivas 67/548/CEE y 1999/45/CE y se modifica el Reglamento (CE) no 1907/2006 [(1)](#ntr1-L_2015197ES.01001001-E0001), y, en particular, su artículo 37, apartado 5,

Considerando lo siguiente:

|  |  |
| --- | --- |
| (1) | El anexo VI, parte 3, del Reglamento (CE) no 1272/2008 contiene dos listas de clasificación y etiquetado armonizados de sustancias peligrosas. La tabla 3.1 recoge la lista de clasificación y etiquetado armonizados de sustancias peligrosas con arreglo a los criterios expuestos en el anexo I, partes 2 a 5, del Reglamento (CE) no 1272/2008. La tabla 3.2 recoge la lista de clasificación y etiquetado armonizados de sustancias peligrosas con arreglo a los criterios expuestos en el anexo VI de la Directiva 67/548/CEE del Consejo [(2)](#ntr2-L_2015197ES.01001001-E0002). |

|  |  |
| --- | --- |
| (2) | Se han remitido a la Agencia Europea de Sustancias y Mezclas Químicas (ECHA) propuestas para la clasificación y el etiquetado armonizados nuevos o actualizados de algunas sustancias, de conformidad con el artículo 37 del Reglamento (CE) no 1272/2008. Tras considerar los dictámenes sobre esas propuestas emitidos por el Comité de Evaluación de Riesgos de la ECHA (RAC), así como las observaciones recibidas de las partes interesadas, se considera necesario introducir o actualizar la clasificación y el etiquetado armonizados de determinadas sustancias mediante la modificación del anexo VI de dicho Reglamento. |

|  |  |
| --- | --- |
| (3) | Por lo que se refiere a la sustancia «ácido nítrico … %» (número CE: 231-714-2), se dispone de nuevos datos científicos sobre la clase de peligro «Toxicidad aguda», que sugieren que podría no ser apropiada la clasificación para esta clase de peligro según lo recomendado en el dictamen del RAC, que se basa en datos más antiguos. Por tanto, esta clase de peligro no debe incluirse en el anexo VI del Reglamento (CE) no 1272/2008 hasta que el RAC haya emitido un dictamen basado en la nueva información, mientras que deben incluirse todas las demás clases de peligro contempladas en el dictamen anterior. |

|  |  |
| --- | --- |
| (4) | En lo que respecta a la sustancia «fenol, dodecil-, ramificado» (número CE: 310-154-3), el RAC se encuentra en la fase de adopción de un nuevo dictamen sobre los límites de concentración específicos que deben aplicarse a la clase de peligro «Tóxico para la reproducción». Por tanto, esta clase de peligro no debe incluirse en el anexo VI del Reglamento (CE) no 1272/2008 hasta que finalice dicho dictamen. |

|  |  |
| --- | --- |
| (5) | No debe exigirse inmediatamente el cumplimiento de las nuevas clasificaciones armonizadas, ya que es necesario un plazo determinado para que los proveedores puedan adaptar a esas nuevas clasificaciones el etiquetado y envasado de las sustancias y mezclas y vender sus existencias actuales. Por otra parte, será necesario un plazo determinado para que los proveedores puedan cumplir sus obligaciones de registro derivadas de las nuevas clasificaciones armonizadas de sustancias clasificadas como carcinógenas, mutágenas o tóxicas para la reproducción, categorías 1A y 1B (tabla 3.1) y categorías 1 y 2 (tabla 3.2), o como muy tóxicas para los organismos acuáticos y que pueden causar efectos duraderos en el medio ambiente acuático, en particular las indicadas en el artículo 23 del Reglamento (CE) no 1907/2006 del Parlamento Europeo y del Consejo [(3)](#ntr3-L_2015197ES.01001001-E0003). |

|  |  |
| --- | --- |
| (6) | De conformidad con las disposiciones transitorias del Reglamento (CE) no 1272/2008, que permiten la aplicación anticipada de las nuevas disposiciones de forma voluntaria, los proveedores deben tener la posibilidad de aplicar las nuevas clasificaciones armonizadas y de adaptar en consecuencia el etiquetado y envasado, de forma voluntaria, antes de que se agote el plazo para su cumplimiento. |

|  |  |
| --- | --- |
| (7) | Las medidas previstas en el presente Reglamento se ajustan al dictamen del Comité establecido en virtud del artículo 133 del Reglamento (CE) no 1907/2006. |

HA ADOPTADO EL PRESENTE REGLAMENTO:

Artículo 1

El anexo VI del Reglamento (CE) no 1272/2008 queda modificado con arreglo al anexo del presente Reglamento.

Artículo 2

No obstante lo dispuesto en el artículo 3, apartado 2, las clasificaciones armonizadas que figuran en el anexo el presente Reglamento podrán aplicarse antes de la fecha indicada en el artículo 3, apartado 2.

Artículo 3

1.   El presente Reglamento entrará en vigor el vigésimo día siguiente al de su publicación en el Diario Oficial de la Unión Europea.

2.   El artículo 1 será aplicable a las sustancias y a las mezclas a partir del 1 de enero de 2017.

El presente Reglamento será obligatorio en todos sus elementos y directamente aplicable en cada Estado miembro.

Hecho en Bruselas, el 24 de julio de 2015.

Por la Comisión

El Presidente

Jean-Claude JUNCKER

---

---

ANEXO

La parte 3 del anexo VI del Reglamento (CE) no 1272/2008 se modifica como sigue:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1) | La tabla 3.1 se modifica como sigue:   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | a) | Las entradas correspondientes a los números de índice 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X y 613-149-00-7 se sustituyen por las entradas correspondientes siguientes:   |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | No de índice | Denominación Química Internacional | No CE | No CAS | Clasificación | | Etiquetado | | | Límites de concentración específicos y factores M | Notas | | Códigos de clase y categoría de peligro | Códigos de indicaciones de peligro | Códigos de pictogramas y palabras de advertencia | Códigos de indicaciones de peligro | Códigos de indicaciones de peligro suplementarias | | 007-004-00-1 | ácido nítrico … % | 231-714-2 | 7697-37-2 | Ox. Liq. 2  Skin Corr. 1A | H272  H314 | GHS03  GHS05  Dgr | H272  H314 | EUH071 | Skin Corr. 1A; H314: C ≥ 20 %  Skin Corr. 1B; H314: 5 % ≤ C < 20 %  Ox. Liq. 2; H272: C ≥ 99 %  Ox. Liq. 3; H272: 99 % > C ≥ 65 % | B | | 015-003-00-2 | fosfuro de calcio; difosfuro de tricalcio | 215-142-0 | 1305-99-3 | Water-react. 1  Acute Tox. 2  Acute Tox. 3  Acute Tox. 1  Eye Dam. 1  Aquatic Acute 1 | H260  H300  H311  H330  H318  H400 | GHS02  GHS06  GHS05  GHS09  Dgr | H260  H300  H311  H330  H318  H400 | EUH029  EUH032 | M = 100 |  | | 031-001-00-4 | arseniuro de galio | 215-114-8 | 1303-00-0 | Repr. 1B  Carc. 1B  STOT RE 1 | H360F  H350  H372 (sistemas respiratorio y hematopoyético) | GHS08  Dgr | H360F  H350  H372 (sistemas respiratorio y hematopoyético) |  |  |  | | 050-008-00-3 | compuestos de tributilestaño, excepto los especificados en otras partes del presente anexo | — | — | Repr. 1B  Acute Tox. 3  Acute Tox. 4 \*  STOT RE 1  Skin Irrit. 2  Eye Irrit. 2  Aquatic Acute 1  Aquatic Chronic 1 | H360FD  H301  H312  H372 \*\*  H315  H319  H400  H410 | GHS08  GHS06  GHS09  Dgr | H360FD  H301  H312  H372 \*\*  H315  H319  H410 |  | \*  STOT RE 1; H372: C ≥ 1 %  STOT RE 2; H373: 0,25 % ≤ C < 1 %  Skin Irrit. 2; H315: C ≥ 1 %  Eye Irrit. 2; H319: C ≥ 1 %  M = 10 | A  1 | | 603-102-00-9 | 1,2-epoxibutano | 203-438-2 | 106-88-7 | Flam. Liq. 2  Carc. 2  Acute Tox. 4 \*  Acute Tox. 4 \*  Acute Tox. 4 \*  STOT SE 3  Skin Irrit. 2  Eye Irrit. 2 | H225  H351  H302  H312  H332  H335  H315  H319 | GHS02  GHS08  GHS07  Dgr | H225  H351  H302  H312  H332  H335  H315  H319 |  |  |  | | 603-197-00-7 | tebuconazol (ISO); 1-(4-clorofenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetil)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. 2  Acute Tox. 4  Aquatic Acute 1  Aquatic Chronic 1 | H361d \*\*\*  H302  H400  H410 | GHS08  GHS07  GHS09  Wng | H361d \*\*\*  H302  H410 |  | M = 1  M = 10 |  | | 606-054-00-7 | isoxaflutol (ISO); 5-ciclopropil-1,2-oxazol-4-il α,α,α-trifluor-2-mesil-p-tolil cetona | — | 141112-29-0 | Repr. 2  Aquatic Acute 1  Aquatic Chronic 1 | H361d \*\*\*  H400  H410 | GHS08  GHS09  Wng | H361d \*\*\*  H410 |  | M = 10  M = 100 |  | | 607-197-00-8 | ácido nonanoico | 203-931-2 | 112-05-0 | Skin Irrit. 2  Eye Irrit. 2  Aquatic Chronic 3 | H315  H319  H412 | GHS07  Wng | H315  H319  H412 |  |  |  | | 613-042-00-5 | imazalilo (ISO); 1-[2-(aliloxi)-2-(2,4-diclorofenil)etil]-1H-imidazol | 252-615-0 | 35554-44-0 | Carc. 2  Acute Tox. 3  Acute Tox. 4  Eye Dam. 1  Aquatic Chronic 1 | H351  H301  H332  H318  H410 | GHS08  GHS06  GHS05  GHS09  Dgr | H351  H301  H332  H318  H410 |  | M = 10 |  | | 613-057-00-7 | dodemorf (ISO); 4-ciclododecil-2,6-dimetilmorfolina | 216-474-9 | 1593-77-7 | Repr. 2  STOT RE 2  Skin Corr. 1C  Skin Sens. 1A  Aquatic Acute 1  Aquatic Chronic 1 | H361d  H373 (hígado)  H314  H317  H400  H410 | GHS08  GHS05  GHS07  GHS09  Dgr | H361d  H373 (hígado)  H314  H317  H410 | EUH071 | M = 1  M = 1 |  | | 613-133-00-X | etridiazol (ISO); 5-etoxi-3-triclorometil-1,2,4-tiadiazol | 219-991-8 | 2593-15-9 | Carc. 2  Acute Tox. 4  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H351  H302  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H351  H302  H317  H410 |  | M = 1  M = 1 |  | | 613-149-00-7 | piridabén (ISO); 2-terc-butil-5-(4-terc-butilbenciltio)-4-cloropiridazin-3(2H)-ona | 405-700-3 | 96489-71-3 | Acute Tox. 3  Acute Tox. 3  Aquatic Acute 1  Aquatic Chronic 1 | H331  H301  H400  H410 | GHS06  GHS09  Dgr | H331  H301  H410 |  | M = 1 000  M = 1 000 |  | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | b) | Se insertan las entradas siguientes de acuerdo con el orden de las entradas recogidas en la tabla 3.1:   |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | No de índice | Denominación Química Internacional | No CE | No CAS | Clasificación | | Etiquetado | | | Límites de concentración específicos y factores M | Notas | | Códigos de clase y categoría de peligro | Códigos de indicaciones de peligro | Códigos de pictogramas y palabras de advertencia | Códigos de indicaciones de peligro | Códigos de indicaciones de peligro suplementarias | | 019-003-00-3 | (E,E)-hexa-2,4-dienoato de potasio | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 | GSH07  Wng | H319 |  |  |  | | 604-092-00-9 | fenol, dodecil-, ramificado [1];  fenol, 2-dodecil-, ramificado;  fenol, 3-dodecil-, ramificado;  fenol, 4-dodecil-, ramificado;  fenol, derivados tetrapropenílicos [2] | 310-154-3 [1] | 121158-58-5 [1]  74499-35-7 [2] | Skin Corr. 1C  Aquatic Acute 1  Aquatic Chronic 1 | H314  H400  H410 | GHS05  GHS09  Dgr | H314  H410 |  | M = 10  M = 10 |  | | 606-148-00-8 | carvona (ISO);  2-metil-5-(prop-1-en-2-il)ciclohex-2-en-1-ona; [1]  d-carvona; (5S)-2-metil-5-(prop-1-en-2-il)ciclohex-2-en-1-ona; [2]  l-carvona; (5R)-2-metil-5-(prop-1-en-2-il)ciclohex-2-en-1-ona [3] | 202-759-5 [1]  218-827-2 [2]  229-352-5 [3] | 99-49-0 [1]  2244-16-8 [2]  6485-40-1 [3] | Skin Sens. 1 | H317 | GHS07  Wng | H317 |  |  |  | | 606-149-00-3 | tembotriona (ISO); 2-{2-cloro-4-(metilsulfonil)-3-[(2,2,2-trifluoroetoxi)metil]benzoil}ciclohexano-1,3-diona | — | 335104-84-2 | Repr. 2  STOT RE 2  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H361d  H373 (ojos, riñones, hígado)  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H361d  H373 (ojos, riñones, hígado)  H317  H410 |  | M = 100  M = 10 |  | | 607-707-00-9 | fenoxaprop-P-etilo (ISO); (2R)-2-{4-[(6-cloro-1,3-benzoxazol-2-il)oxi]fenoxiy}propanoato de etilo | — | 71283-80-2 | STOT RE 2  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H373 (riñones)  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H373 (riñones)  H317  H410 |  | M = 1  M = 1 |  | | 607-708-00-4 | ácido octanoico | 204-677-5 | 124-07-2 | Skin Corr. 1C  Aquatic Chronic 3 | H314  H412 | GHS05  Dgr | H314  H412 |  |  |  | | 607-709-00-X | ácido decanoico | 206-376-4 | 334-48-5 | Skin Irrit. 2  Eye Irrit. 2  Aquatic Chronic 3 | H315  H319  H412 | GHS07  Wng | H315  H319  H412 |  |  |  | | 607-710-00-5 | ácido 1,2-bencenodicarboxílico, éster dihexílico, ramificado y linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD | GHS08  Dgr | H360FD |  |  |  | | 607-711-00-0 | espirotetramat (ISO); carbonato de (5s,8s)-3-(2,5-dimetilfenil)-8-metoxi-2-oxo-1-azaspiro[4,5]dec-3-en-4-ilo y etilo | — | 203313-25-1 | Repr. 2  STOT SE 3  Eye Irrit. 2  Skin Sens. 1 A  Aquatic Acute 1  Aquatic Chronic 1 | H361fd  H335  H319  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H361fd  H335  H319  H317  H410 |  | M = 1  M = 1 |  | | 607-712-00-6 | acetato de dodemorf; acetato de 4-ciclododecil-2,6-dimetilmorfolin-4-io | 250-778-2 | 31717-87-0 | Repr. 2  STOT RE 2  Skin Corr. 1C  Skin Sens. 1 A  Aquatic Chronic 1 | H361d  H373 (hígado)  H314  H317  H410 | GHS08  GHS05  GHS07  GHS09  Dgr | H361d  H373 (hígado)  H314  H317  H410 | EUH071 | M = 1 |  | | 607-713-00-1 | fenpiroximato (ISO); 4-[({(E)-[(1,3-dimetil-5-fenoxi-1H-pirazol-4-il)metilen]amino}oxi)metil]benzoato de terc-butilo | — | 134098-61-6 | Acute Tox. 3  Acute Tox. 2  Skin Sens. 1B  Aquatic Acute 1  Aquatic Chronic 1 | H301  H330  H317  H400  H410 | GHS06 GHS09  Dgr | H301  H330  H317  H410 |  | M = 100  M = 1 000 |  | | 607-714-00-7 | triflusulfurón-metilo; 2-({[4-(dimetilamino)-6-(2,2,2-trifluoroetoxi)-1,3,5-triazin-2-il]carbamoil}sulfamoil)-3-metilbenzoato de metilo | — | 126535-15-7 | Carc. 2  Aquatic Acute 1  Aquatic Chronic 1 | H351  H400  H410 | GHS08  GHS09  Wng | H351  H410 |  | M = 100  M = 10 |  | | 607-715-00-2 | bifenazato (ISO); 2-(4-metoxibifenil-3-il)hidrazinacarboxilato de isopropilo | 442-820-5 | 149877-41-8 | STOT RE 2  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H373  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H373  H317  H410 |  | M = 1  M = 1 |  | | 613-319-00-0 | imidazol | 206-019-2 | 288-32-4 | Repr. 1B  Acute Tox. 4  Skin Corr. 1C | H360D  H302  H314 | GHS08  GHS07  GHS05  Dgr | H360D  H302  H314 |  |  |  | | 613-320-00-6 | lenacilo (ISO); 3-ciclohexil-6,7-dihidro-1H-ciclopenta[d]pirimidina-2,4(3H,5H)-diona | 218-499-0 | 2164-08-1 | Carc. 2  Aquatic Acute 1  Aquatic Chronic 1 | H351  H400  H410 | GHS08  GHS09  Wng | H351  H410 |  | M = 10  M = 10 |  | | 616-213-00-2 | mandipropamid (ISO); 2-(4-clorofenil)-N-{2-[3-metoxi-4-(prop-2-in-1-iloxi)fenil]etil}-2-(prop-2-in-1-iloxi)acetamida | — | 374726-62-2 | Aquatic Acute 1  Aquatic Chronic 1 | H400  H410 | GHS09  Wng | H410 |  | M = 1  M = 1 |  | | 616-214-00-8 | metosulam (ISO); N-(2,6-dicloro-3-metilfenil)-5,7-dimetoxi[1,2,4]triazolo[1,5-a]pirimidina-2-sulfonamida | — | 139528-85-1 | Carc. 2  STOT RE 2  Aquatic Acute 1  Aquatic Chronic 1 | H351  H373 (ojos, riñones)  H400  H410 | GHS08  GHS09  Wng | H351  H373 (ojos, riñones)  H410 |  | M = 1 000  M = 100 |  | | 616-215-00-3 | dimetenamida-P (ISO); 2-cloro-N-(2,4-dimetil-3-tienil)-N-[(2S)-1-metoxipropan-2-il]acetamida | — | 163515-14-8 | Acute Tox. 4  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H302  H317  H400  H410 | GHS07  GHS09  Wng | H302  H317  H410 |  | M = 10  M = 10 |  | | 616-216-00-9 | flonicamida (ISO); N-(cianometil)-4-(trifluorometil)piridina-3-carboxamida | — | 158062-67-0 | Acute Tox. 4 | H302 | GHS07  Wng | H302 |  |  |  | | 616-217-00-4 | sulfoxaflor (ISO); [metil(oxo){1-[6-(trifluorometil)-3-piridil]etil}-λ6-sulfaniliden]cianamida | — | 946578-00-3 | Acute Tox. 4  Aquatic Acute 1  Aquatic Chronic 1 | H302  H400  H410 | GHS07  GHS09  Wng | H302  H410 |  | M = 1  M = 1 |  | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2) | La tabla 3.2 se modifica como sigue:   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | a) | Las entradas correspondientes a los números de índice 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X y 613-149-00-7 se sustituyen por las entradas correspondientes siguientes:   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | No de índice | Denominación Química Internacional | No CE | No CAS | Clasificación | Etiquetado | Límites de concentración | Notas | | 007-004-00-1 | ácido nítrico … % | 231-714-2 | 7697-37-2 | O; R8  C; R35 | O; C  R: 8-35  S: (1/2-)26-28- 36/37/39-45-63 | O; R8: C ≥ 65 %  C; R35: C ≥ 20 %  C; R34: 5 % ≤ C < 20 % | B | | 015-003-00-2 | fosfuro de calcio; difosfuro de tricalcio | 215-142-0 | 1305-99-3 | F; R15/29  T+; R26/28  Xn; R21  R32  Xi; R38-41  N; R50 | F; T+; N  R: 15/29-21-26/28-32-38-41-50  S:(1/2-)26-28-30-36/37/39-43-45-60-61 | N; R50: C ≥ 0,25 % |  | | 031-001-00-4 | arseniuro de galio | 215-114-8 | 1303-00-0 | Repr. Cat. 2; R60  Carc. Cat. 2; R45  T; R48/23 | T  R: 45-48/23-60  S: 45-53 |  | E | | 050-008-00-3 | compuestos de tributilestaño, excepto los especificados en otras partes del presente anexo | — | — | Repr. Cat. 2; R60-61  T; R25-48/23/25  Xn; R21  Xi; R36/38  N; R50-53 | T; N  R: 21-25-36/38-48/23/25-50/53-60-61  S: 45-53-60-61 | T; R25: C ≥ 2,5 %  Xn; R22: 0,25 % ≤ C < 2,5 %  Xn: R21: C ≥ 1 %  T; R48/23/25: C ≥ 1 %  Xn; R48/20/22: 0,25 % ≤ C < 1 %  Xi; R36/38: C ≥ 1 %  N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % | A  1 | | 603-102-00-9 | 1,2-epoxibutano | 203-438-2 | 106-88-7 | F; R11  Carc. Cat. 3; R40  Xn; R20/21/22  Xi; R36/37/38 | F; Xn  R: 11-20/21/22-36/37/38-40-  S: (2-)9-16-29-36/37-46 |  |  | | 603-197-00-7 | tebuconazol (ISO); 1-(4-clorofenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetil)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. Cat. 3; R63  Xn; R22  N; R50-53 | Xn; N  R: 22-50/53-63  S: (2-)22-36/37-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 606-054-00-7 | isoxaflutol (ISO); 5-ciclopropil-1,2-oxazol-4-il α,α,α-trifluor-2-mesil-p-tolil cetona | — | 141112-29-0 | Repr. Cat. 3; R63  N; R50-53 | Xn; N  R: 50/53-63  S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 607-197-00-8 | ácido nonanoico | 203-931-2 | 112-05-0 | Xi; R36/38  N; R51-53 | Xi; N  R: 36/38-51/53  S: (2-)46-61 |  |  | | 613-042-00-5 | imazalilo (ISO); 1-[2-(aliloxi)-2-(2,4-diclorofenil)etil]-1H-imidazol | 252-615-0 | 35554-44-0 | Carc. Cat. 3; R40  Xn; R20/22  Xi; R41  N; R51-53 | Xn; N  R: 20/22-40-41-51/53  S: (2-)26-36/37/39-46-61 |  |  | | 613-057-00-7 | dodemorf (ISO); 4-ciclododecil-2,6-dimetilmorfolina | 216-474-9 | 1593-77-7 | Repr. Cat. 3; R63  C; R34  R43  N; R50-53 | C; N  R: 34-43-50/53-63  S: (1/2-)26-28-36/37/39-45-60-61 | C; R34: C ≥ 10 %  Xi; R36/37/38: 5 % ≤ C < 10 %  N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 613-133-00-X | etridiazol (ISO); 5-etoxi-3-triclorometil-1,2,4-tiadiazol | 219-991-8 | 2593-15-9 | Carc. Cat. 3; R40  Xn; R22  R43  N; R50-53 | Xn; N  R: 22-40-43-50/53  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 613-149-00-7 | piridabén (ISO); 2-terc-butil-5-(4-terc-butilbenciltio)-4-cloropiridazin-3(2H)-ona | 405-700-3 | 96489-71-3 | T; R23/25  N; R50-53 | T; N  R: 23/25-50/53  S: (1/2-)36/37-45-60-61 | N; R50-53: C ≥ 0,025 %  N; R51-53: 0,0025 % ≤ C < 0,025 %  R52-53: 0,00025 % ≤ C < 0,0025 % |  | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | b) | Se insertan las entradas siguientes de acuerdo con el orden de las entradas recogidas en la tabla 3.2:   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | No Índice | Denominación Química Internacional | No CE | No CAS | Clasificación | Etiquetado | Límites de concentración | Notas | | 019-003-00-3 | (E,E)-hexa-2,4-dienoato de potasio | 246-376-1 | 24634-61-5 | Xi; R36 | Xi  R: 36  S: (2-)25-46 |  |  | | 604-092-00-9 | fenol, dodecil-, ramificado [1];  fenol, 2-dodecil-, ramificado;  fenol, 3-dodecil-, ramificado;  fenol, 4-dodecil-, ramificado;  fenol, derivados tetrapropenílicos [2] | 310-154-3 [1]-[2] | 121158-58-5 [1]  74499-35-7 [2] | C; R34  N; R50-53 | C; N  R: 34-50/53  S: (1/2-)26-36/37/39-45-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 606-148-00-8 | carvona (ISO);  2-metil-5-(prop-1-en-2-il)ciclohex-2-en-1-ona; [1]  d-carvona; (5S)-2-metil-5-(prop-1-en-2-il)ciclohex-2-en-1-ona; [2]  l-carvona; (5R)-2-metil-5-(prop-1-en-2-il)ciclohex-2-en-1-ona [3] | 202-759-5 [1]  218-827-2 [2]  229-352-5 [3] | 99-49-0 [1]  2244-16-8 [2]  6485-40-1 [3] | R43 | Xi  R: 43  S: (2-)24-37 |  |  | | 606-149-00-3 | tembotriona (ISO); 2-{2-cloro-4-(metilsulfonil)-3-[(2,2,2-trifluoroetoxi)metil]benzoil}ciclohexano-1,3-diona |  | 335104-84-2 | Repr. Cat. 3; R63  Xn; R48/22  R43  N; R50-53 | Xn; N  R: 43-48/22-50/53-63  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,25 %  N; R51-53: 0,025 % ≤ C < 0,25 %  R52-53: 0,0025 % ≤ C < 0,025 % |  | | 607-707-00-9 | fenoxaprop-P-etilo (ISO); (2R)-2-{4-[(6-cloro-1,3-benzoxazol-2-il)oxi]fenoxi}propanoato de etilo | — | 71283-80-2 | Xn; R48/22  R43  N; R50-53 | Xn; N  R: 43-48/22-50/53  S: (2-)24-37-46-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 607-708-00-4 | ácido octanoico | 204-677-5 | 124-07-2 | C; R34  N; R51-53 | C; N  R: 34-51/53  S: (1/2-)26-36/37/39-45-61 |  |  | | 607-709-00-X | ácido decanoico | 206-376-4 | 334-48-5 | Xi; R36/38  N; R51-53 | Xi; N  R: 36/38-51/53  S: (2-)25-46-61 |  |  | | 607-710-00-5 | ácido 1,2-bencenodicarboxílico, éster dihexílico, ramificado y linear | 271-093-5 | 68515-50-4 | Repr. Cat. 2; R60-61 | T  R: 60-61  S: 53-45 |  |  | | 607-711-00-0 | espirotetramat (ISO); carbonato de (5s,8s)-3-(2,5-dimetilfenil)-8-metoxi-2-oxo-1-azaspiro[4,5]dec-3-en-4-ilo y etilo | — | 203313-25-1 | Repr. Cat. 3; R62-63  Xi; R36/37  R43  N; R50-53 | Xn; N  R: 36/37-43-50/53-62-63  S: (2-)36/37-60-61 | Xi; R43: C ≥ 0,1 %  N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 607-712-00-6 | acetato de dodemorf; acetato de 4-ciclododecil-2,6-dimetilmorfolin-4-io | 250-778-2 | 31717-87-0 | Repr. Cat. 3; R63  C; R34  R43  N; R51-53 | C; N  R: 34-43-51/53-63  S: (1/2-)26-28-36/37/39-45-61 | C; R34: C ≥ 10 %  Xi; R36/37/38: 5 % ≤ C < 10 % |  | | 607-713-00-1 | fenpiroximato (ISO); 4-[({(E)-[(1,3-dimetil-5-fenoxi-1H-pirazol-4-il)metilen]amino}oxi)metil]benzoato de terc-butilo | — | 134098-61-6 | T+; R26  Xn; R22  R43  N; R50-53 | T+; N  R: 22-26-43-50/53  S: (1/2-)28-36/37-45-60-61-63 | N; R50-53: C ≥ 0,25 %  N; R51-53: 0,025 % ≤ C < 0,25 %  R52-53: 0,0025 % ≤ C < 0,025 % |  | | 607-714-00-7 | triflusulfurón-metilo; 2-({[4-(dimetilamino)-6-(2,2,2-trifluoroetoxi)-1,3,5-triazin-2-il]carbamoil}sulfamoil)-3-metilbenzoato de metilo | — | 126535-15-7 | Carc. Cat. 3; R40  N; R50-53 | Xn; N  R: 40-50/53  S: (2-)36/37-60-61 | N; R50-53: C ≥ 0,25 %  N; R51-53: 0,025 % ≤ C < 0,25 %  R52-53: 0,0025 % ≤ C < 0,025 % |  | | 607-715-00-2 | bifenazato (ISO); 2-(4-metoxibifenil-3-il)hidrazinacarboxilato de isopropilo | 442-820-5 | 149877-41-8 | R43  N; R50-53 | Xi; N  R: 43-50/53  S: (2-)24-37-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 613-319-00-0 | imidazol | 206-019-2 | 288-32-4 | Repr. Cat 2; R61  Xn; R22  C; R34 | T; C  R: 22-34-61  S: 53-45 |  |  | | 613-320-00-6 | lenacilo (ISO); 3-ciclohexil-6,7-dihidro-1H-ciclopenta[d]pirimidina-2,4(3H,5H)-diona | 218-499-0 | 2164-08-1 | Carc. Cat. 3; R40  N; R50-53 | Xn; N  R: 40-50/53  S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 616-213-00-2 | mandipropamid (ISO); 2-(4-clorofenil)-N-{2-[3-metoxi-4-(prop-2-in-1-iloxi)fenil]etil}-2-(prop-2-in-1-iloxi)acetamida | — | 374726-62-2 | N; R50-53 | N  R: 50/53  S: 60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 616-214-00-8 | metosulam (ISO); N-(2,6-dicloro-3-metilfenil)-5,7-dimetoxi[1,2,4]triazolo[1,5-a]pirimidina-2-sulfonamida | — | 139528-85-1 | Carc. Cat. 3; R40  Xn; R48/22  N; R50-53 | Xn; N  R: 40-48/22-50/53  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,025 %  N; R51-53: 0,0025 % ≤ C < 0,025 %  R52/53: 0,00025 % ≤ C < 0,0025 % |  | | 616-215-00-3 | dimetenamida-P (ISO); 2-cloro-N-(2,4-dimetil-3-tienil)-N-[(2S)-1-metoxipropan-2-il]acetamida | — | 163515-14-8 | Xn; R22  R43  N; R50-53 | Xn; N  R: 22-43-50/53  S: (2-)24-37-60-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 616-216-00-9 | flonicamida (ISO); N-(cianometil)-4-(trifluorometil)piridina-3-carboxamida | — | 158062-67-0 | Xn; R22 | Xn  R: 22  S: (2-)46 |  |  | | 616-217-00-4 | sulfoxaflor (ISO); [metil(oxo){1-[6-(trifluorometil)-3-piridil]etil}-λ6-sulfaniliden]cianamida | — | 946578-00-3 | Xn; R22  N; R50-53 | Xn; N  R: 22-50/53  S: (2-)60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | |

---

[Top](#document1)